Cholinesterase inhibitors: drugs looking for a disease? (Q33238993)

24 July 2017

2 references

30 January 2021

8 October 2022

Cholinesterase inhibitors: drugs looking for a disease? (English)

1 reference

cholinesterase inhibitors

24 July 2017

1 reference

2 October 2019

1 reference

2 October 2019

1 reference

2 October 2019

1 reference

2 October 2019

1 reference

30 January 2021

2

Nicola Vanacore

1 reference

24 July 2017

Marina Maggini

1

1 reference

24 July 2017

Roberto Raschetti

series ordinal

3

1 reference

24 July 2017

language of work or name

English

0 references

publication date

11 April 2006

1 reference

24 July 2017

1 April 2006

6 references

22 March 2019

25 April 2019

17 June 2019

2 October 2019

30 January 2021

8 October 2022

7 references

24 July 2017

22 March 2019

25 April 2019

17 June 2019

2 October 2019

30 January 2021

8 October 2022

3

1 reference

24 July 2017

4

1 reference

24 July 2017

e140

1 reference

Creative Commons Attribution 4.0 International

24 July 2017

6 references

22 March 2019

25 April 2019

17 June 2019

2 October 2019

30 January 2021

on focus list of Wikimedia project

8 October 2022

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1434488

Clinical trials in mild cognitive impairment: lessons for the future

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1434488

Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1434488

Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1434488

Vitamin E and donepezil for the treatment of mild cognitive impairment

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1434488

External validity of randomised controlled trials: "to whom do the results of this trial apply?".

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1434488

Rivastigmine for dementia associated with Parkinson's disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1434488

Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1434488

Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1434488

Donepezil in vascular dementia: a viewpoint by David S. Geldmacher

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1434488

Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1434488

Cholinesterase inhibitors for dementia with Lewy bodies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1434488

Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

21 June 2018

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1434488

21 June 2018

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.0030140

Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1434488

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1434488

Seeing what you want to see in randomised controlled trials: versions and perversions of UKPDS data. United Kingdom prospective diabetes study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1434488

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1434488

New drug treatment for Alzheimer's disease: lessons for healthcare policy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1434488

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1434488

Donepezil in vascular dementia: a randomized, placebo-controlled study

21 June 2018

1 reference

Crossref

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.0030140

Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.0030140

A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer's disease

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1434488

NICE proposes to withdraw Alzheimer's drugs from NHS.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1434488

Donepezil in vascular dementia: a viewpoint by Gustavo C. Román

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1434488

Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1434488

Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1434488

Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1434488

An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1434488

Combined effect of age and severity on the risk of dementia in Parkinson's disease

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/16597173

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Mild cognitive impairment is not a clinical entity and should not be treated

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/16597173

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1371/JOURNAL.PMED.0030140

1 reference

24 July 2017

1 reference

24 July 2017

1 reference